Larimar Therapeutics (LRMR)Director bought ~$167K
Thomas Edward Hamilton, Director at Larimar Therapeutics, bought ~$167K of Larimar Therapeutics shares.
- ~$167K
- Approx. value · 50K sh @ $3.34
- 715K
- Holds after · shares reported
- Traded
- Jul 6, 2026
- Filed
- Jul 8, 2026
The story around this disclosure
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.
- May 14, 2026Company filing · Form 8-K · Results, Other newsReported its results, and reported other company news
- Jul 6, 2026 · this disclosureInsiderDirector purchased ~$167K of LRMR shares in the open market
What came next
- Aug 4, 2026Company filing · Form 8-K · Results, Other newsReported its results, and reported other company news
- Sep 29, 2026Company filing · Form 8-K · Executive changeChanged a top executive or board member“The Board of Directors (the “Board”) of Larimar Therapeutics, Inc. (the “Company”) appointed John B. Harlow, Jr. as the Company’s President and Chief Operating Officer pursuant to the terms of an employment agreement with Mr. Harlow (the “Employment Agreement”), effective as of September 29, 2026 (the “Effective Date”).”
How to read SEC Form 4
Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.
Full guide: What is an SEC Form 4?
What else is on file for Larimar Therapeutics
OQRO holds no insider, Congress, fund or contract record for Larimar Therapeutics dated in the last 90 days.
These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its LRMR page.
Other recent filings by Thomas Edward Hamilton, Director
The full history of Thomas Edward Hamilton, Director is on the profile page.
How this filing works
Other disclosures at Larimar Therapeutics
- SEC Form 13F-HRMay 15, 2026
- SEC Form 4Mar 3, 2026
- SEC Form 4Mar 3, 2026
- SEC Form 4Mar 3, 2026
- SEC Form 4Mar 3, 2026
- SEC Form 4Mar 2, 2026
Everything OQRO holds on this company is on its LRMR page.
This is one filing. OQRO holds the rest
Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.
OQRO Pro is a paid subscription. You see the price before you pay
OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data